Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8939 results

  1. Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)

    Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA412

  2. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

    Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

    Technology appraisal guidance
    Published
    20 December 2017
    View recommendations

    Sections for TA495

  3. Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

    Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.

    Technology appraisal guidance
    Published
    20 December 2017

    Sections for TA496

  4. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

    Technology appraisal guidance
    Published
    7 August 2024
    View recommendations

    Sections for TA993

  5. Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension

    In development Reference number: GID-IPG10318 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  6. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development

  7. Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10404 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  8. Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

    Interventional procedures guidance
    In development

  9. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  10. eXroid for internal haemorrhoids

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. Respirasense

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  12. High Definition – transcranial Electrical Stimulation (HD-tES) for fibromyalgia

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  13. Robotic assisted bronchoscopy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  14. Percutaneous transluminal radiofrequency sympathetic denervation of the renal artery for glycemic control

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  15. Low-level laser therapy (photobiomodulation) for oral neuropathic pain

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation